Aegerion Pharmaceuticals Inc. plans a January launch of its homozygous familial hypercholesterolemia drug Juxtapid (lomitapide) with a target population that appears to be broader than FDA expectations.
The total adjustable market for the drug could be as many as 3,000, CEO Marc Beers said during a Dec. 24 conference call. FDA, in announcing approval of Juxtapid, said there are about one in one million people in the U.S. with HoFH